Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Announces Positive Preliminary Results of Its Fluzone High-Dose Vaccine Study


Monday, 26 Aug 2013 01:01am EDT 

Reuters reported that Sanofi SA said that a large clinical trial showed its Fluzone High-Dose vaccine to be more effective at preventing influenza in adults aged 65 and older than a standard dose of Fluzone. Sanofi SA said it plans to submit the full clinical study report to the U.S. Food and Drug Administration for review by early 2014 and will seek to modify to the label for Fluzone High-Dose vaccine to reflect the superior efficacy data in this age group. In the study, which included roughly 30,000 participants, Fluzone High-Dose vaccine was 24.2% more effective in preventing influenza in adults 65 years of age and older than Fluzone vaccine. Fluzone High-Dose vaccine was licensed for sale by the FDA in 2009 under an accelerated approval process that included a requirement that Sanofi SA complete a large-scale confirmatory study. 

Company Quote

77.01
0.1 +0.13%
24 Jul 2014